210 related articles for article (PubMed ID: 26349962)
1. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
[TBL] [Abstract][Full Text] [Related]
2. Effect of brefeldin A and castanospermine on resistant cell lines as supplements in anticancer therapy.
Wojtowicz K; Januchowski R; Sosińska P; Nowicki M; Zabel M
Oncol Rep; 2016 May; 35(5):2896-906. PubMed ID: 26985570
[TBL] [Abstract][Full Text] [Related]
3. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
4. vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Anticancer Res; 2017 Jun; 37(6):3015-3023. PubMed ID: 28551640
[TBL] [Abstract][Full Text] [Related]
5. Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zaorska K; Sosińska P; Klejewski A; Brązert M; Nowicki M; Zabel M
J Ovarian Res; 2016 Oct; 9(1):65. PubMed ID: 27756418
[TBL] [Abstract][Full Text] [Related]
6. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
[TBL] [Abstract][Full Text] [Related]
7. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sterzyſska K; Sosiſska P; Andrzejewska M; Zawierucha P; Nowicki M; Zabel M
Int J Biochem Cell Biol; 2016 Sep; 78():248-259. PubMed ID: 27443528
[TBL] [Abstract][Full Text] [Related]
9. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
10. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.
Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN
Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805
[TBL] [Abstract][Full Text] [Related]
11. [The mechanism of topotecan resistance in ovarian cancer cell line].
Jia P; Wu SB; Li F; Xu Q; Wu MF; Liao GN; Lu YP; Ma D
Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):139-42. PubMed ID: 15196431
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype.
Kramer R; Weber TK; Arceci R; Ramchurren N; Kastrinakis WV; Steele G; Summerhayes IC
Br J Cancer; 1995 Apr; 71(4):670-5. PubMed ID: 7710927
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance.
Fujita T; Washio K; Takabatake D; Takahashi H; Yoshitomi S; Tsukuda K; Ishibe Y; Ogasawara Y; Doihara H; Shimizu N
Int J Cancer; 2005 Nov; 117(4):670-82. PubMed ID: 15945097
[TBL] [Abstract][Full Text] [Related]
16. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ
Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272
[TBL] [Abstract][Full Text] [Related]
17. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance.
Zhang FF; Zhu YF; Zhao QN; Yang DT; Dong YP; Jiang L; Xing WX; Li XY; Xing H; Shi M; Chen Y; Bruce IC; Jin J; Ma X
Eur J Pharmacol; 2014 Sep; 738():83-90. PubMed ID: 24877693
[TBL] [Abstract][Full Text] [Related]
18. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
[TBL] [Abstract][Full Text] [Related]
19. [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].
Jia P; Wu SB; Xu Q; Wu MF; Gao QL; Liao GN; Lu YP; Ma D
Ai Zheng; 2003 Dec; 22(12):1296-300. PubMed ID: 14693055
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab directly inhibits P-glycoprotein function in vitro independently of EGFR binding.
Chu C; Noël-Hudson MS; Bénard J; Ha-Duong T; Allaoui F; Farinotti R; Bonhomme-Faivre L
Eur J Pharm Sci; 2015 Aug; 76():18-26. PubMed ID: 25930120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
